He P, Zou Y, Qiu J, et al. - Researchers aimed at examining the correlation between KRAS/NRAS/BRAF mutations and metabolic parameters of pretreatment ¹⁸F-FDG PET/CT in colorectal cancer (CRC). All 85 included patients with CRC underwent PET/CT before surgery. The primary tumor was assessed via histopathological examination and analysis of the gene mutational status. In 54.12% (46/85) patients, KRAS/NRAS/BRAF mutations were detected. In addition, KRAS/NRAS/BRAF-mutation groups showed significantly higher SUVmax and T/NT when compared with the wild-type group. Overall findings suggest that for predicting the KRAS/NRAS/BRAF mutational status in CRC patients, the potential surrogate imaging indicators include T/NT ratio and SUVmax.